Abacavir lamivudine zidovudine contraindications

Revision as of 16:45, 9 January 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Abacavir lamivudine zidovudine}} {{CMG}}; {{AE}} {{SS}} ==Contraindications== TRIZIVIR Tablets are contraindicated in patients with: *previously demonstrated hyp...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Abacavir lamivudine zidovudine
TRIZIVIR® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Contraindications

TRIZIVIR Tablets are contraindicated in patients with:

  • previously demonstrated hypersensitivity to abacavir or any other component of the product. NEVER restart TRIZIVIR or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status [see Warnings and Precautions (5.1), Adverse Reactions (6)].
  • hepatic impairment [see Use in Specific Populations (8.7)].[1]

References

  1. "TRIZIVIR (ABACAVIR SULFATE, LAMIVUDINE, AND ZIDOVUDINE) TABLET, FILM COATED [VIIV HEALTHCARE COMPANY]". Retrieved 9 January 2014.

Adapted from the FDA Package Insert.